Biogaia AB
STO:BIOG B

Watchlist Manager
Biogaia AB Logo
Biogaia AB
STO:BIOG B
Watchlist
Price: 110.2 SEK 0.64% Market Closed
Market Cap: 11.1B SEK
Have any thoughts about
Biogaia AB?
Write Note

Biogaia AB
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biogaia AB
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Biogaia AB
STO:BIOG B
Capital Expenditures
-kr48.6m
CAGR 3-Years
-45%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Capital Expenditures
-kr8.4m
CAGR 3-Years
-66%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Capital Expenditures
-kr156m
CAGR 3-Years
-73%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Capital Expenditures
-kr57.4m
CAGR 3-Years
-10%
CAGR 5-Years
-31%
CAGR 10-Years
-16%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Capital Expenditures
-kr3.4B
CAGR 3-Years
-9%
CAGR 5-Years
18%
CAGR 10-Years
-42%
BioArctic AB
STO:BIOA B
Capital Expenditures
-kr7.4m
CAGR 3-Years
16%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

Biogaia AB
Glance View

Market Cap
11.1B SEK
Industry
Biotechnology

BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.

BIOG B Intrinsic Value
112.88 SEK
Undervaluation 2%
Intrinsic Value
Price

See Also

What is Biogaia AB's Capital Expenditures?
Capital Expenditures
-48.6m SEK

Based on the financial report for Dec 31, 2023, Biogaia AB's Capital Expenditures amounts to -48.6m SEK.

What is Biogaia AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-29%

Over the last year, the Capital Expenditures growth was -171%. The average annual Capital Expenditures growth rates for Biogaia AB have been -45% over the past three years , -29% over the past five years .

Back to Top